Skip to main content
placeholder image

Population implications of lipid-lowering for secondary prevention of coronary heart disease: Data from the 1996 Scottish Health Survey

Journal Article


Abstract


  • Patients with coronary heart disease (CHD) or other forms of atherosclerotic vascular disease who have serum total cholesterol ≥5.0 mmol/l should have priority for lipid-lowering treatment with HMG Co-A reductase inhibitors (statins). Knowledge of the proportion of the population needing treatment for secondary prevention is important to those who must provide the resources. We have examined the prevalence of self-reported myocardial infarction (MI), angina, stroke, or peripheral vascular disease (PVD) with serum total cholesterol ≥5.0 mmol/l, in a random sample of 3963 subjects aged 35 - 64 years from the 1995 Scottish Health Survey. The prevalence of these cardiovascular diagnoses and serum cholesterol ≥5.0 mmol/l increased in men from 1.7% at age 35 - 39 years to 23.1% at age 60 - 64 years, and in women from 1.3% at age 35 - 39 years to 15.1% at age 65 - 64 years. Overall 7.8% of the Scottish population aged 35 - 64 years might benefit statin treatment for secondary prevention, comprising 2.9% with a history of MI; 2.9% with angina; 0.6% with a history of stroke, and 1.5% with a history of PVD - all with total cholesterol ≥5.0 mmol/l (table). Percentages of Scottish men and women with total cholesterol >5.0mmol/l Age (years) MI Angina Stroke PVD Total 35-39 0.2 0.2 0.1 0.9 1.5 40-44 0.9 0.7 0.3 0.6 2.5 45-49 1.9 1.3 0.4 0.9 4.6 50-54 3.6 2.4 0.3 2.6 8.9 55-59 4.8 2.3 0.7 2.2 13.0 60-64 6.7 8.1 1.6 2.4 18.7 Total 35-64 2.9 2.9 0.6 1.5 7.8 95% CI 2.3-3.4 2.3-3.4 0.3-0.8 1.1-1.9 6.9-8.6 Guidelines for the use of HMG Co-A reductase inhibitors should take into account the considerable workload and financial resources needed even to implement secondary prevention of CHD.

Publication Date


  • 1999

Published In


Citation


  • Haq, I. U., Wallis, E. J., Yeo, W. W., Jackson, P. R., Ritchie, L. D., Isles, C. G., & Ramsay, L. E. (1999). Population implications of lipid-lowering for secondary prevention of coronary heart disease: Data from the 1996 Scottish Health Survey. Heart, 81(SUPPL. 1).

Scopus Eid


  • 2-s2.0-4243716937

Web Of Science Accession Number


Volume


  • 81

Issue


  • SUPPL. 1

Abstract


  • Patients with coronary heart disease (CHD) or other forms of atherosclerotic vascular disease who have serum total cholesterol ≥5.0 mmol/l should have priority for lipid-lowering treatment with HMG Co-A reductase inhibitors (statins). Knowledge of the proportion of the population needing treatment for secondary prevention is important to those who must provide the resources. We have examined the prevalence of self-reported myocardial infarction (MI), angina, stroke, or peripheral vascular disease (PVD) with serum total cholesterol ≥5.0 mmol/l, in a random sample of 3963 subjects aged 35 - 64 years from the 1995 Scottish Health Survey. The prevalence of these cardiovascular diagnoses and serum cholesterol ≥5.0 mmol/l increased in men from 1.7% at age 35 - 39 years to 23.1% at age 60 - 64 years, and in women from 1.3% at age 35 - 39 years to 15.1% at age 65 - 64 years. Overall 7.8% of the Scottish population aged 35 - 64 years might benefit statin treatment for secondary prevention, comprising 2.9% with a history of MI; 2.9% with angina; 0.6% with a history of stroke, and 1.5% with a history of PVD - all with total cholesterol ≥5.0 mmol/l (table). Percentages of Scottish men and women with total cholesterol >5.0mmol/l Age (years) MI Angina Stroke PVD Total 35-39 0.2 0.2 0.1 0.9 1.5 40-44 0.9 0.7 0.3 0.6 2.5 45-49 1.9 1.3 0.4 0.9 4.6 50-54 3.6 2.4 0.3 2.6 8.9 55-59 4.8 2.3 0.7 2.2 13.0 60-64 6.7 8.1 1.6 2.4 18.7 Total 35-64 2.9 2.9 0.6 1.5 7.8 95% CI 2.3-3.4 2.3-3.4 0.3-0.8 1.1-1.9 6.9-8.6 Guidelines for the use of HMG Co-A reductase inhibitors should take into account the considerable workload and financial resources needed even to implement secondary prevention of CHD.

Publication Date


  • 1999

Published In


Citation


  • Haq, I. U., Wallis, E. J., Yeo, W. W., Jackson, P. R., Ritchie, L. D., Isles, C. G., & Ramsay, L. E. (1999). Population implications of lipid-lowering for secondary prevention of coronary heart disease: Data from the 1996 Scottish Health Survey. Heart, 81(SUPPL. 1).

Scopus Eid


  • 2-s2.0-4243716937

Web Of Science Accession Number


Volume


  • 81

Issue


  • SUPPL. 1